RxDoctor Payments Data

Daniel Nussbaum

Surgical Oncology · Durham, NCNPI 1942590047

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,100 of the $5,698 with a category attached, or 89.5%. Asensus Surgical, Inc. accounts for 89.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $5,100 and has fallen 94.2% since, to $296 in 2025.

$5,698in general payments, 2019–2025

Across 7 payments — averaging $814.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Asensus Surgical, Inc.$5K
  • Springworks Therapeutics, Inc.$226
  • Medtronic$135
  • Boston Scientific$87
  • Conmed Corporation$76
  • Medical Device Business Services, Inc.$74
$246,383in research payments, 2019–2025

Across 16 payments — averaging $15,399 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$246K

What the payments were for

  • Consulting fees$5,10089%
  • Food & beverage$59811%

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,698 in reported general payments places this provider in the 70th percentile of 34 surgical oncology providers in North Carolina.

See all surgical oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,708
Medicare patients
101
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →